Bedrijfsoverzicht
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical entity dedicated to the development and commercialization of therapeutic solutions specifically targeting hyperuricemia-related diseases within the Canadian market. The company operates within the broader healthcare sector, functioning more specifically in the biotechnology industry, which implies a focus on innovative drug discovery and clinical trial execution rather than traditional manufacturing or retail distribution. The current market capitalization stands at $3.47M, while annual revenue data is not publicly reported, and the employee count is listed as N/A. These valuation metrics indicate that the company is in an early development phase with a very small market cap, suggesting that its financial resources are primarily allocated toward advancing clinical programs rather than generating substantial revenue or employing a large workforce.
Financiële gezondheid
The reported net income for the trailing twelve months is $-2,656,304, while EBITDA stands at $-2,508,489; the near-identical figures suggest that interest and tax expenses are minimal, but the significant gap between revenue and net income reflects the heavy operational burn typical of pre-commercial biotechnology firms where revenue is often N/A. Free cash flow is recorded at $-1,856,310, which indicates that the company is currently consuming cash reserves to fund its research and development activities rather than generating surplus liquidity for expansion or shareholder returns. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard indicator for early-stage biotechs where costs associated with clinical trials and R&D far exceed current sales, resulting in no positive contribution to margins yet. The company holds $864,514 in cash against a debt obligation of $37,287, creating a debt-to-equity ratio of 1.79, which suggests a highly leveraged balance sheet relative to equity but manageable given the low absolute debt amount. Despite the high debt-to-equity figure, the current ratio of 2.10 indicates that the company possesses more than double the current assets required to cover its short-term liabilities, pointing to adequate short-term liquidity management. Return on Equity is -98.0% and Return on Assets is -46.8%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic of firms in the late-stage clinical development phase.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to the lack of positive earnings, whereas the forward P/E is 3.11; this stark difference implies that the market is valuing the company based on anticipated future profitability rather than current earnings history. The price-to-book ratio is 8.33, indicating that the stock trades at a significant premium over its book value, reflecting the market's high valuation of the company's intangible assets and potential clinical pipeline despite current losses. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA of -1.05 are utilized to assess value when traditional earnings multiples are unavailable, with the negative EV/EBITDA confirming the company's unprofitable status. The stock has traded between a 52-week low of $1.73 and a 52-week high of $7.05, meaning the current price sits at a position that reflects significant volatility within this specific trading range. The beta value is 0.09, which signifies that the stock exhibits extremely low price volatility relative to the broader market, moving independently of general market fluctuations.
Growth & Income
Revenue growth and earnings growth rates are listed as N/A, which prevents a direct comparison of earnings growth speed against revenue growth; however, the absence of positive earnings implies that the company is not yet in a growth phase characterized by profitable scaling. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio, meaning the entire financial focus is on reinvesting all available capital into research, development, and commercialization efforts rather than paying dividends to shareholders. This reinvestment strategy is standard for biotechnology companies in the late-stage clinical phase, where capital preservation and pipeline advancement are prioritized over income generation. Consequently, the overall growth and income profile is defined by a reliance on external capital or cash reserves to fuel expansion, with no current mechanism for providing income through dividends or earnings growth.